Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA COMPOUND vs CLENPIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: management of muscle spasms, tension headaches
Cleansing of the colon as a preparation for colonoscopy in adults
1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Carisoprodol: approximately 2-4 hours in adults with normal renal function. Meprobamate: approximately 10-12 hours. The prolonged half-life of meprobamate contributes to accumulation with repeated dosing, especially in elderly or renally impaired patients, leading to increased risk of sedation and dependence.
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite); aspirin is hydrolyzed to salicylic acid via esterases in the liver and plasma.
Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally.
Carisoprodol and its active metabolite meprobamate are primarily excreted renally. Approximately 60% of a dose is eliminated as unchanged carisoprodol and meprobamate in urine, with the remainder as various hydroxylated metabolites. Less than 1% is eliminated in feces. Meprobamate undergoes hepatic metabolism, and about 10-20% is excreted unchanged in urine.
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
Carisoprodol: approximately 60% bound to plasma proteins, primarily albumin. Meprobamate: approximately 15-25% bound to plasma proteins.
Sodium picosulfate: <5% bound to plasma proteins
Carisoprodol: Vd approximately 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding. Meprobamate: Vd about 0.7 L/kg.
Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration)
Oral: Carisoprodol is well absorbed with bioavailability >90%. The absorption rate may be slightly reduced with food, but extent is not significantly affected.
Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption
Cr Cl <30 m L/min: avoid use due to aspirin component; Cr Cl 30-50 m L/min: reduce dose or extend interval; monitor for carisoprodol accumulation.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-59 m L/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B).
Not recommended for children under 12 years; safety and efficacy not established.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Initiate at lowest dose (1 tablet); avoid use in patients with Cr Cl <30 m L/min; monitor for CNS depression and bleeding risk.
No specific dose adjustment required solely based on age. Consider renal function (e GFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment).
No FDA black box warning.
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
Dependence and withdrawal: Carisoprodol can cause dependence, abuse, and withdrawal symptoms after prolonged use,Sedation: May impair mental or physical abilities; caution with driving or operating machinery,Bleeding risk: Aspirin component increases risk of bleeding, especially with alcohol, anticoagulants, or existing bleeding disorders,Hypersensitivity: Allergic reactions including anaphylaxis can occur
Risk of fluid and electrolyte abnormalities,Cardiac arrhythmias due to electrolyte imbalance,Seizures associated with electrolyte abnormalities,Renal impairment,Mucosal ulceration,Use with caution in patients with impaired gag reflex, reflux, or aspiration risk,Colonic mucosal aphthous ulcerations
History of acute intermittent porphyria,Hypersensitivity to carisoprodol, meprobamate, aspirin, or any component,Severe hepatic or renal impairment,Gastrointestinal bleeding or peptic ulcer disease (active),Children with viral infections (Reye's syndrome risk),Third trimester of pregnancy (aspirin component)
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Hypersensitivity to any component,Severe renal impairment (e GFR <30 m L/min/1.73m²)
Avoid alcohol. Aspirin may cause gastrointestinal irritation; take with food or a full glass of water to reduce risk. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
Avoid solid food during bowel preparation. Only clear liquids (water, clear broth, black coffee/tea, clear fruit juices without pulp, gelatin, popsicles) are permitted. Do not consume milk, cream, or any dairy products. Avoid red or purple colored liquids that may be mistaken for blood during colonoscopy. Do not consume alcohol.
Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin component (if present in compound) is associated with increased risk of neural tube defects and fetal hemorrhage if used in third trimester. Avoid use during pregnancy unless benefit outweighs risk.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus.
Carisoprodol and its active metabolite meprobamate are excreted in breast milk. M/P ratio not well established. Concentrations may reach clinical significance. Potential for infant sedation, hypotonia, or withdrawal. Avoid breastfeeding while on this medication.
Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration.
No established dosing adjustments for pregnancy. Due to increased renal clearance during pregnancy, consider that standard doses may be less effective. However, lack of safety data generally contraindicates use. If absolutely necessary, use lowest effective dose for shortest duration.
No dose adjustment recommendations available due to lack of pharmacokinetic studies in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal blood flow) may affect drug disposition; use lowest effective dose and ensure adequate hydration. No specific dose reduction recommended.
Soma Compound contains carisoprodol (a centrally acting muscle relaxant) and aspirin (an NSAID). Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with a history of substance abuse, porphyria, or G6PD deficiency. Monitor for signs of CNS depression, especially when combined with alcohol or other sedatives. Aspirin increases bleeding risk; avoid in patients with bleeding disorders or those on anticoagulants. Do not use in children or adolescents with viral infections due to risk of Reye's syndrome.
CLENPIQ (sodium picosulfate, magnesium oxide, and citric acid) is a colonoscopy preparation. Ensure adequate hydration before, during, and after use. Common adverse effects include nausea, vomiting, and abdominal distension. Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min), gastrointestinal obstruction, ileus, or known hypersensitivity. Avoid use within 1 hour of antacids or medications that affect gastrointestinal motility.
Take exactly as prescribed; do not increase dose or frequency.,Do not drive or operate heavy machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report any signs of bleeding (bruising, black stools, blood in urine) or allergic reactions (rash, swelling, difficulty breathing).,Do not use in children or teenagers with chickenpox or flu symptoms due to risk of Reye's syndrome.,This medication may be habit-forming; do not stop abruptly without consulting your doctor.,Store at room temperature away from moisture and heat.
Take CLENPIQ as a split-dose regimen: one bottle the evening before and one bottle the morning of the colonoscopy.,Do not take any other laxatives or bowel preparations concurrently.,Stay hydrated by drinking clear liquids before and after each dose.,Do not eat solid food during the preparation period; only clear liquids are allowed.,Common side effects include nausea, bloating, and abdominal cramps; contact your doctor if severe or persistent.,Avoid driving or operating machinery if you feel dizzy or lightheaded.,Inform your doctor of all medications, especially diuretics, ACE inhibitors, ARBs, NSAIDs, or any drugs affecting kidney function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA COMPOUND vs CLENPIQ, answered by our medical review team.
SOMA COMPOUND is a Skeletal Muscle Relaxant Combination that works by Carisoprodol is a centrally acting muscle relaxant that acts through its metabolite meprobamate, which modulates GABA-A receptors and inhibits neuronal activity in the reticular formation and spinal cord. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. CLENPIQ is a Laxative that works by Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA COMPOUND and CLENPIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA COMPOUND is: 1-2 tablets (carisoprodol 200mg/aspirin 325mg) orally 4 times daily.. The standard adult dose of CLENPIQ is: Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA COMPOUND and CLENPIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA COMPOUND is classified as Category C. Carisoprodol (Soma) is FDA Pregnancy Category C. Inadequate human data; animal studies suggest risk. Not recommended in first trimester due to potential teratogenicity. Aspirin com. CLENPIQ is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.